8:00 am Coffee Room Opens
8:50 am Chair’s Opening Remarks
9:00 am Improving Patient Identification Through Precision Diagnostics – CDx for Mobocertinib
Synopsis
- Validated CDx test is critical for identifying all EGFR exon 20 insertion patients
eligible for treatment with mobocertinib - A CDx for tissue sample testing was validated and approved by the FDA
simultaneously with mobocertinib - A liquid biopsy NGS test has been validated for detection of EGFR exon 20
insertions in NSCLC patients
Progress in Mutation-Driven NSCLC Drug Development in Earlier Lines of Therapy
9:30 am The RAF/MEK Clamp VS-6766 for Treatment of KRAS & BRAF Mutant NSCLC
Synopsis
- Exploring anti-tumor activity across multiple MAPK pathway alterations
- Ongoing VS-6766 combinations with FAK, KRAS G12C or mTOR inhibitors
- Revealing new combinations with EGFR inhibitors
10:00 am Increase NSCLC Drug Commercialization Success by Incorporating Biomarker/Diagnostic Solutions into Clinical Trials
Synopsis
- Biomarker-informed care can improve patient outcomes, but ~50% of NSCLC
of patients currently do not have biomarker results prior to starting first-line
treatment - Challenges with clinical trial enrollment can delay NSCLC drug commercialization
- Drug developers that incorporate biomarkers into their oncology clinical trials are
known to be 5x more successful at obtaining FDA approval. - How a diagnostic partner with deep expertise in both lung disease and rapid
turnaround liquid biopsy, a broad clinical trial site network, and experience
enrolling thousands of NSCLC patients sets drug developers up for success
10:30 am Morning Refreshments
11:30 am The Bispecific Antibody MCLA-129 Impairs EGFR Inhibitor Resistant NSCLC Tumor Growth by Targeting EGFR & c-MET
Synopsis
- Exploring the upregulation of c-MET signaling has been associated with
resistance to EGFR inhibition - Delving into MCLA-129: a bispecific antibody that blocks the signaling of EGFR as
well as c-MET, to inhibit tumor growth and survival - Understand how MCLA-129 utilizes ADCC-enhancement technology, which
increases its cell-killing potential by immune cells
12:00 pm Inhibition of the WNT/beta catenin Pathway in NSCLC
Synopsis
- Understand the WNT/beta catenin pathway’s importance as a target in NSCLC
- Explore the new therapeutics in development to inhibit this target
- Combination with EGFR inhibitors has potential to impact disease progression
Immune Checkpoint Inhibitors & Rational Combinations to Improve Outcomes in Earlier Lines of Therapy
12:30 pm A Soluble LAG-3 Protein (Eftilagimod Alpha) with an Anti-PD-1 Antibody (Pembrolizumab): Results of a Phase II Study in NSCLC
Synopsis
- An MHC class II agonist (eftilagimod) used as an antigen presenting cell (APC) activator combined with an immune checkpoint inhibitor (ICI)
- Results in first (114 patients) and second (36 PD-X refractory patients) lines NSCLC
- A systemic APC activator injected s.c. plus an ICI: a potent combination for PDL-1
unselected patients
1:00 pm Lunch & Networking
Amplifying the Patient Voice to Improve Trials
2:00 pm Patient Advocacy Groups as Partners in Drug Development
Synopsis
- PAGs like LUNGevity Foundation support patients with cancer in multiple ways, including by funding transformative research on disease biology, detection, and treatment
- LUNGevity has a demonstrated history of engaging stakeholders in the drug development ecosystem to address pain points and working together towards implementable solutions
2:30 pm BLOODPAC: Screening, Early Detection Challenges & Opportunities Ahead
3:00 pm Chair’s Closing Remarks & End of Summit
